Peptide Therapy After 60: What Older Adults Need to Know About Benefits, Risks, and Safe Access

Peptide therapy for adults over 60 is clinically viable — and increasingly relevant. Growth hormone output drops by roughly 14% per decade after 30. By the time you reach your sixties, you are operating with a fraction of the hormonal and regenerative signalling your body once had. That biological reality drives the muscle loss, fat accumulation, poor sleep, and slow recovery that many older adults accept as inevitable.

They are not inevitable. Targeted peptide therapy can restore signalling pathways that age has suppressed. But the protocols, the risk profile, and the monitoring requirements at 60+ are meaningfully different from what a 40-year-old would need. This guide breaks all of it down.

What Is Peptide Therapy and Why Does It Matter After 60?

Peptide therapy uses short amino acid chains to bind specific receptors and trigger targeted biological responses. Unlike broad hormone replacement, peptides work upstream — stimulating your body's own production rather than replacing it.

After 60, several critical systems are in decline simultaneously:

• Growth hormone (GH) secretion — drops significantly with age, reducing IGF-1 levels that govern muscle maintenance, fat metabolism, and tissue repair
• Insulin sensitivity — worsens progressively, increasing metabolic syndrome risk
• Inflammatory signalling — chronic low-grade inflammation ("inflammaging") accelerates cellular damage
• Sleep architecture — slow-wave sleep decreases, impairing the overnight GH pulse that drives recovery

Peptides that target the GH axis — secretagogues like sermorelin, CJC-1295, and ipamorelin — work by stimulating the pituitary to release more of your own growth hormone. Others, like BPC-157, act on tissue repair pathways. GLP-1 receptor agonists target insulin secretion and appetite regulation.

Each class has a distinct mechanism, distinct benefits, and distinct risk considerations for the older adult.

Which Peptides Are Most Relevant for Older Adults?

The most clinically relevant peptides for seniors fall into four categories. The right choice depends on your specific physiology, lab values, and health goals.,

Growth Hormone Secretagogues (GHS)

These are the most widely used peptides in older adults. They stimulate the hypothalamus and pituitary to release GH naturally, avoiding the suppression risk of exogenous GH.

Sermorelin is a GHRH analogue and the most established option for older adults. It mirrors the body's natural growth hormone-releasing hormone. Clinical data supports improvements in body composition, sleep quality, and energy in patients over 60 when IGF-1 levels are confirmed suboptimal at baseline.1

CJC-1295 + Ipamorelin is the most commonly prescribed stack for metabolic and body composition goals. CJC-1295 provides sustained GHRH stimulation; ipamorelin adds a ghrelin-mimetic pulse that amplifies GH release with minimal cortisol or prolactin elevation. For more on how this combination works, see Meto's deep dive on the CJC-1295 and Ipamorelin stack.

Tesamorelin is an FDA-approved GHRH analogue with the strongest clinical evidence base. Originally approved for HIV-associated lipodystrophy, it has shown consistent visceral fat reduction in multiple trials in non-HIV adults — a meaningful benefit given visceral adiposity's role in cardiovascular and metabolic risk after 60.2

BPC-157

Body Protection Compound-157 is a synthetic peptide derived from a gastric protein. It has demonstrated potent tissue repair, anti-inflammatory, and gut-protective effects in preclinical research. For older adults dealing with joint degradation, musculoskeletal injury, or gut motility issues, it is a logical adjunct. Note: BPC-157's regulatory status is currently under active FDA review as part of the 2026 PCAC peptide evaluation process.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide are technically peptide-based therapeutics. For older adults managing obesity, insulin resistance, or type 2 diabetes risk, they carry perhaps the strongest evidence base of any metabolic peptide therapy available today. Meto covers these in dedicated medication guides for semaglutide and tirzepatide.

Mitochondrial Peptides

MOTS-c and humanin are mitochondria-derived peptides that decline with age. They activate AMPK, improve insulin sensitivity, and reduce systemic inflammation. The research is compelling — and covered fully in Meto's MOTS-c metabolic health guide and the humanin and SHLP-2 deep dive.

The Core Benefits of Peptide Therapy for Senior Metabolic Health

The benefits most relevant to adults over 60 cluster around four domains. These are grounded in clinical evidence, not anti-aging marketing.

1. Body Composition

Age-related muscle loss (sarcopenia) accelerates after 60, with losses of 1–2% of muscle mass per year.3 GH secretagogues improve lean body mass by elevating IGF-1, which drives protein synthesis in skeletal muscle. A randomised trial of GHRH analogues in older adults showed significant lean mass gains versus placebo over 26 weeks, alongside reductions in truncal fat.4

2. Metabolic Function and Insulin Sensitivity

Insulin resistance is nearly universal in older adults with abdominal obesity. Tesamorelin reduces visceral adipose tissue — the metabolically active fat that drives insulin resistance directly. MOTS-c activates AMPK pathways that improve GLUT4 glucose transport, restoring cellular glucose uptake without the GI side effects of metformin.5 For adults managing prediabetes or metabolic syndrome, this is clinically significant.

3. Sleep Quality and Recovery

GH secretion is pulsatile and largely nocturnal. By 60, slow-wave sleep is substantially reduced, and the overnight GH pulse is blunted. Ipamorelin, in particular, is associated with improved slow-wave sleep architecture and enhanced overnight recovery.6 Better sleep means better cortisol regulation, better inflammatory control, and faster physical recovery — all compounding benefits for active seniors.

4. Bone Density and Joint Health

Low IGF-1 correlates directly with reduced bone mineral density.7 GH secretagogues that elevate IGF-1 may support bone remodelling, particularly relevant for older women post-menopause and men experiencing andropause-related testosterone decline. BPC-157 shows anti-inflammatory effects at joint sites, though human clinical data remains limited.

The Real Risks: What Older Adults Must Understand

Peptide therapy at 60+ carries real risks that are often understated by providers who lack geriatric metabolic expertise. Do not skip this section.

Elevated IGF-1 and Cancer Risk

IGF-1 is a growth signal. That is precisely why it builds muscle and supports repair. It is also why elevated IGF-1 raises theoretical concerns about cancer promotion in individuals with pre-existing malignancy or strong genetic risk.8 Any peptide protocol in an adult over 60 must include a pre-treatment cancer screen and should not be initiated in individuals with active or recent cancer history without oncology input.

Glucose Dysregulation

GH is counter-regulatory to insulin. Elevated GH — even pituitary-derived GH stimulated by secretagogues — can worsen insulin sensitivity transiently, particularly in the first 4–8 weeks of therapy.9 Adults with existing insulin resistance or prediabetes require close glucose monitoring. HbA1c and fasting insulin are non-negotiable baseline labs before starting any GH secretagogue.

Fluid Retention and Carpal Tunnel

Elevated GH causes sodium and water retention. In older adults with compromised cardiac or renal function, this can precipitate oedema or exacerbate hypertension. Starting doses in adults over 60 should be 30–50% lower than those used in younger patients, titrated slowly based on IGF-1 response and symptom tolerance.10

Drug Interactions

Many adults over 60 are on multiple medications. Corticosteroids blunt GH response. Thyroid hormone affects GH metabolism. Insulin dose may require adjustment. A full medication review before starting any peptide protocol is not optional — it is the standard of care.

Polypharmacy and Compounding Quality

Adults over 60 are disproportionately affected by compounding pharmacy quality issues. Peptides must be sourced through licensed 503A or 503B pharmacies under physician prescription. The Meto guide on gray market vs. legal compounded peptides in 2026 is required reading before sourcing any therapy.

Peptide Therapy After 60: Risk vs. Benefit Summary

What Does Peptide Therapy for Elderly Patients Look Like in Practice?

A well-structured protocol for a 65-year-old with suboptimal IGF-1, sarcopenia, and visceral adiposity might look like this:

1. Baseline labs — IGF-1, GH stimulation assessment, HbA1c, fasting insulin, CMP, CBC, lipid panel, PSA (men), thyroid panel, DEXA scan for bone density
2. Peptide selection — typically sermorelin or low-dose CJC-1295/ipamorelin for GH axis support; tesamorelin if visceral fat is the primary target
3. Starting dose — 50% of standard adult dose, titrated up over 4–6 weeks based on IGF-1 response and side effect tolerance
4. Administration — subcutaneous injection, typically at bedtime to align with natural GH pulsatility
5. 8-week reassessment — IGF-1, fasting glucose, HbA1c, symptom review, body composition measurement
6. Ongoing monitoring — every 8–12 weeks; annual cancer screening maintained

For full pre-treatment lab guidance, Meto's growth hormone peptide therapy labs guide covers every required biomarker in detail.

Peptide Therapy Adults Over 60: Who Is and Is Not a Candidate

Strong Candidates

• Adults 60+ with documented low IGF-1 on serum testing
• Individuals with sarcopenia confirmed by DEXA or functional testing
• Active seniors experiencing delayed recovery, poor sleep, and reduced energy not explained by other pathology
• Adults managing visceral obesity with inadequate response to diet and exercise
• Individuals already on andropause or menopause hormone therapy who want adjunctive metabolic support

Poor Candidates or Contraindicated

• Any history of active cancer (especially hormone-sensitive: prostate, breast, colon)
• Uncontrolled diabetes (HbA1c above 8.5%)
• Severe cardiac or renal impairment
• Active intracranial pathology (GH secretagogues stimulate pituitary; caution applies)
• Individuals sourcing peptides without physician supervision or from unverified suppliers

The Regulatory Landscape in 2026: What GH Peptides Are Legally Available?

The legal status of compounded peptides has shifted significantly in 2025–2026. Sermorelin remains on the FDA 503A Bulks List and is legally compoundable. CJC-1295 and ipamorelin are available through 503A compounding pharmacies under physician prescription. BPC-157 and TB-500 are under active advisory panel review (scheduled for July 2026).

Tesamorelin carries the strongest regulatory standing — it is an FDA-approved drug (Egrifta) and can also be compounded for off-label use under physician prescription.

The key principle: any GH peptide aging protocol in the US must flow through a licensed prescriber and a licensed compounding pharmacy. There is no legitimate over-the-counter route. Any website selling injectable peptides without a prescription is operating outside legal and safety standards.

How to Access Peptide Therapy Safely as an Adult Over 60

Here is the process, step by step:

1. Choose a clinician with metabolic and geriatric expertise. Not every telehealth provider has the depth to manage older adults on peptide therapy. You need someone who will order the right labs, not just the popular ones.
2. Complete a comprehensive metabolic panel. Meto's Comprehensive Metabolic Panel ($199) and Longevity Panel ($399) are designed specifically to give clinicians the baseline picture they need.
3. Disclose your full medication list. Every drug. Every supplement. Interactions matter far more at 60+ than at 40.
4. Start low and go slow. If a provider proposes full adult dosing from day one, that is a red flag.
5. Commit to monitoring. Peptide therapy without regular lab follow-up is not safe care — it is experimentation. Monitoring is what separates therapeutic benefit from preventable harm.
6. Source only from licensed pharmacies. Your clinician should specify a 503A or 503B compounding pharmacy. If they do not, ask why.

Peptide Therapy and Menopause or Andropause: Addressing the Overlap

Adults over 60 often arrive at peptide therapy in the context of established hormonal decline — menopause in women, andropause in men.

For women, GH secretagogues used alongside menopause hormone therapy show additive benefits on body composition and bone density. The two therapies act on different axes and are generally well tolerated in combination when properly monitored. Meto covers menopause-specific metabolic care at meto.co/menopause and meto.co/perimenopause.

For men, andropause-related testosterone decline compounds the GH axis deterioration. Low testosterone and low IGF-1 together produce a significantly worse body composition and metabolic picture than either alone. If testosterone is suboptimal, addressing it alongside — not after — GH secretagogue therapy will produce better outcomes. See Meto's andropause page for more.

Conclusion

Peptide therapy for adults over 60 is not anti-aging fantasy. It is a targeted clinical intervention for documented hormonal and metabolic decline. The evidence supports its use for sarcopenia, visceral adiposity, poor sleep, and insulin resistance — all of which worsen predictably with age.

But the risk profile is real. Cancer screening, glucose monitoring, conservative dosing, and pharmacy quality are non-negotiable. The difference between benefit and harm is clinical rigour.

If you are over 60 and experiencing the symptoms described here — fatigue, body composition changes, poor recovery, worsening metabolic markers — the first step is not sourcing peptides. It is getting the right labs and the right clinician.

Get a tailored peptide care plan designed for your age and health status at Meto.

Frequently Asked Questions

Is peptide therapy safe for adults over 60?

It can be — with the right clinical oversight. Adults over 60 require lower starting doses, pre-treatment cancer screening, glucose monitoring, and more frequent follow-up than younger patients. Safety depends almost entirely on clinical rigour, not the peptides themselves. Do not start any GH peptide without baseline IGF-1, HbA1c, and a full medication review.

Which peptide is best for seniors dealing with muscle loss and fatigue?

Sermorelin or a low-dose CJC-1295/ipamorelin combination is the most commonly used GH secretagogue approach for sarcopenia and fatigue in adults over 60. Tesamorelin is the strongest option if visceral fat reduction is the primary goal. The right choice depends on your lab values and comorbidities — there is no universal answer without baseline testing.

Can peptide therapy interact with medications I am already taking?

Yes. Corticosteroids, insulin, thyroid medications, and several cardiovascular drugs all interact with GH axis peptides. A full medication reconciliation before initiating any peptide protocol is mandatory. This is one of the most common points of failure when adults pursue peptide therapy outside supervised clinical care.

How long before an adult over 60 sees results from GH peptide therapy?

Sleep quality often improves within 2–4 weeks. Body composition changes — measurable reductions in fat mass and increases in lean mass — typically become apparent at the 8–12 week mark. IGF-1 normalisation on labs is usually visible at the 6–8 week assessment. Bone density changes require 12+ months to document on DEXA.

Do I need to inject peptides, or are there alternatives?

Most GH secretagogues require subcutaneous injection for adequate bioavailability. Oral and nasal delivery exists for some peptides (notably BPC-157), but the evidence for bioavailability equivalence is weaker. For adults with dexterity issues, a clinician can arrange injection training and supervision. GLP-1 receptor agonists like semaglutide are also injectable but use very fine auto-injector pens that most adults manage without difficulty.

Does insurance cover peptide therapy for older adults?

Coverage varies. Tesamorelin (Egrifta) is FDA-approved and may be covered for specific indications. GLP-1 receptor agonists like semaglutide are increasingly covered for obesity and diabetes. Compounded secretagogues like sermorelin and CJC-1295/ipamorelin are typically self-pay. Meto's clinical team can help clarify what your plan covers and what the out-of-pocket costs look like for your specific situation.